The pharmaceutical industry is an economic sector that is very rich and active, consisting mainly of research, manufacture and marketing of medicines. Its success is illustrated by the fact that it is one of the most profitable industries in the world. Some of the best pharmaceutical and biotech companies are Sanofi-Aventis, Johnson and Pfizer.
As part of a study, this paper will deal with multiple aspects of these companies like: economic development, social involvement of the state and market, competition, international openness, productivity and employment. It shall see how the pharmaceutical sector faces the various challenges it encounters. Some of the challenges include the decline of innovation in different research laboratories, generic competition and the rising power of biotechnology.
All these developments are bearing down on the profitability of the laboratories, and through this, on the future of its businesses. However, the pharmaceutical sector will never really be threatened. This is because of the strength it has and the strategies it can come up with to innovate and to cope with any situation.
The pharmaceutical industry is classified in the industry of consumer goods and has three business segments: the manufacture of basic pharmaceutical products , the manufacture of medicines and the manufacture of other pharmaceutical products . The pharmacies are classified in the trade sector.
The pharmaceutical sector is structured around the pharmaceutical and biotechnology companies that operate in a highly regulated environment, fine markets, chemicals suppliers, service providers in research and development, the different market segments (specialties, ethical, generic drugs and OTC) and distribution channels and individuals marketing .
It is a sector supported by sound structural fundamentals such as the aging population, population growth, unmet medical needs, medical drive innovation. However, the pharmaceutical industry remains largely controlled by the national health insurance. As a result, companies have seen their productivity decline, and that is due to a tightening of the regulatory frame work and the fear of increased adverse effects of drugs on the market. Many also face the loss of operating licenses on many of their discoveries that fall into the public domain, which promotes the development of generic importance.
The dynamics of the global pharmaceutical market is supported by the aging population and unmet medical needs. Little influenced by economic cycles, the development of the pharmaceutical market is based on structural factors of socio-economic development, ensuring a bright future for this sector. Moreover, the advent of chemistry has made the pharmaceutical industry one of the most profitable sectors of the 20th century.
However, in recent years there has been a gradual decline of the industry, due to the slow down in the pace of discovery of new molecules to bring to market an innovative drug.
Also, major pharmaceutical companies have had to develop a range of new strategies to maintain their growth rate. These strategies are mainly in three areas: research and development (R & D), industrial structure and intellectual property.
The pharmaceutical sector is represented by a set of institutions and the public and private organizations vary widely.
It brings together trade unions, in addition to the National Order of Pharmacists (which includes all pharmacists of a particular mode of exercise or a group of pharmaceutical companies).
Tags: The pharmaceutical industry; economic development; competition and challenges faced by this industry
[...] Outflows mainly concern the chemical and pharmaceutical industry. III. Sector performance A. Participation in the growth From 2002 to 2006, the ratio of value added to GDP is between a range of 7000 and 8000. This report is constantly changing these 5 years with the exception of 2004, when this report is 7032.08 against 7772.65 in 2003. On average, it evolves on the 5 years. The decrease in 2004 was probably due to a lack of customs supervision which has created many flagrant violations of pharmaceutical regulations. [...]
[...] Analysis of industry structure A. Degree of concentration on industry 71% of the activity of the pharmaceutical industry brings in "making medicine" industry. The top 10 companies in this sector are: company name Code NAF Sanofi Winthrop industrie 24.4 .C Sanofi Pasteur 24.4 .C Sanofi-Aventis France 24.4 .C Gloxo Wellcome Production 24.4 .C Bristrol Myers Squibb 24.4 .C Lilly France 24.4 .C Boiron 24.4 .C Laboratoire Gloxosmithkline 24.4 .C Laboratoires Merck Sharp & Dohme 24.4 .C Chibret Pfizer 24.4 .C Source Sessi - Year 2007 In 2007, the turnover of the pharmaceutical industry in France was billion euros billion euros in turnover in refundable fireplace billion euros in CA generic (which still represents an increase of 17% compared to the turnover of the previous year) billion euros in turnover in hospital medicine billion euros in turnover in non- refundable and 19 pharmacies MoUs CA for export. [...]
[...] It was extended by the Ministry of Labor, which makes it applicable to all companies in the pharmaceutical industry. National Collective Convention of the Pharmaceutical Industry is divided into three parts: ♣ General Clauses ♣ Rider I "Classifications and Salaries", introduces a single classification system for all employees, regardless of the category to which they belong. This classification, which contains 11 levels divided into 26 groups, was constructed from so-called "classifying criteria" criteria: complexity, responsibility, autonomy, knowledge and experience required. [...]
[...] According to WHO, this herbal medicine is considered a traditional medicine and still massively used in some countries, including countries in the developing world. This is an unconventional medicine because of the absence of clinical study. • A practice based on scientific advances that research active plant extracts. The extracts are standardized assets identified. This practice leads to herbal medicines and according to the regulations in force in the country, the movement of herbal medicines is subject to authorization on the market (AMM). This is called pharmacognosy or pharmaceutical biology. [...]
[...] The bargaining power of suppliers determines the costs of raw materials and other inputs. We must understand that the social security system is the most important of all players on the final customer of the drug market. It has the benefit of the insured, a major trading power to steer the market and stimulate local industry, as well as to streamline costs and maximize the benefits of social security coverage to their insureds. In its specific environment, an organization must evaluate the intensity of the power exercised over her clients and suppliers. [...]
APA Style reference
For your bibliographyOnline reading
with our online readerContent validated
by our reading committee
